BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17084567)

  • 1. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids.
    Hadinoto K; Phanapavudhikul P; Kewu Z; Tan RB
    Int J Pharm; 2007 Mar; 333(1-2):187-98. PubMed ID: 17084567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery.
    Hadinoto K; Zhu K; Tan RB
    Int J Pharm; 2007 Aug; 341(1-2):195-206. PubMed ID: 17467934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
    Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
    Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanical stability of hollow spherical nano-aggregates as ultrasound contrast agent.
    Hadinoto K
    Int J Pharm; 2009 Jun; 374(1-2):153-61. PubMed ID: 19446772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
    Cheow WS; Ng ML; Kho K; Hadinoto K
    Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effervescent dry powder for respiratory drug delivery.
    Ely L; Roa W; Finlay WH; Löbenberg R
    Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hollow spherical nanoparticulate aggregates as potential ultrasound contrast agent: shell thickness characterization.
    Hadinoto K; Cheow WS
    Drug Dev Ind Pharm; 2009 Oct; 35(10):1167-79. PubMed ID: 19555237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The PulmoSphere™ platform for pulmonary drug delivery.
    Weers J; Tarara T
    Ther Deliv; 2014 Mar; 5(3):277-95. PubMed ID: 24592954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
    Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
    Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying.
    Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P
    Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation.
    Sebti T; Amighi K
    Eur J Pharm Biopharm; 2006 May; 63(1):51-8. PubMed ID: 16380243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-micro- and nanoparticles for pulmonary delivery.
    Klingler C; Müller BW; Steckel H
    Int J Pharm; 2009 Jul; 377(1-2):173-9. PubMed ID: 19446621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical characterization and water vapor sorption of organic solution advanced spray-dried inhalable trehalose microparticles and nanoparticles for targeted dry powder pulmonary inhalation delivery.
    Li X; Mansour HM
    AAPS PharmSciTech; 2011 Dec; 12(4):1420-30. PubMed ID: 22038473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
    Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
    J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The preparation and application of pulmonary surfactant nanoparticles as absorption enhancers in insulin dry powder delivery.
    Zhang Y; Zhu J; Tang Y; Chen X; Yang Y
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1059-65. PubMed ID: 19640250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of inhalable dry powder formulation of basic fibroblast growth factor.
    Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
    Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.